You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Suppliers and packagers for generic pharmaceutical drug: prochlorperazine edisylate


✉ Email this page to a colleague

« Back to Dashboard


prochlorperazine edisylate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Amneal PROCHLORPERAZINE EDISYLATE prochlorperazine edisylate INJECTABLE;INJECTION 214192 ANDA Amneal Pharmaceuticals LLC 70121-1580-5 25 VIAL in 1 CARTON (70121-1580-5) / 2 mL in 1 VIAL (70121-1580-1) 2022-12-12
Amneal PROCHLORPERAZINE EDISYLATE prochlorperazine edisylate INJECTABLE;INJECTION 214192 ANDA Amneal Pharmaceuticals LLC 70121-1580-7 10 VIAL in 1 CARTON (70121-1580-7) / 2 mL in 1 VIAL (70121-1580-1) 2022-12-12
Avet Lifesciences PROCHLORPERAZINE EDISYLATE prochlorperazine edisylate INJECTABLE;INJECTION 204147 ANDA Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-294-41 25 VIAL in 1 PACKAGE (23155-294-41) / 2 mL in 1 VIAL (23155-294-31) 2012-03-26
Avet Lifesciences PROCHLORPERAZINE EDISYLATE prochlorperazine edisylate INJECTABLE;INJECTION 204147 ANDA Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-294-42 10 VIAL in 1 PACKAGE (23155-294-42) / 2 mL in 1 VIAL (23155-294-31) 2012-03-26
Avet Lifesciences PROCHLORPERAZINE EDISYLATE prochlorperazine edisylate INJECTABLE;INJECTION 204147 ANDA Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-523-41 10 VIAL in 1 PACKAGE (23155-523-41) / 2 mL in 1 VIAL (23155-523-31) 2015-06-26
Avet Lifesciences PROCHLORPERAZINE EDISYLATE prochlorperazine edisylate INJECTABLE;INJECTION 204147 ANDA Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-523-42 25 VIAL in 1 PACKAGE (23155-523-42) / 2 mL in 1 VIAL (23155-523-31) 2015-06-26
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Prochlorperazine Edisylate

Last updated: July 30, 2025

Introduction

Prochlorperazine Edisylate is a widely used antipsychotic and antiemetic agent, chiefly prescribed for nausea, vomiting, schizophrenia, and anxiety-related disorders. As a critical component in various therapeutic regimens, maintaining a reliable supply chain is essential for pharmaceutical manufacturers, healthcare providers, and regulatory agencies. This report explores the key suppliers, manufacturing landscape, and market dynamics associated with Prochlorperazine Edisylate, providing actionable insights for stakeholders seeking procurement or investment opportunities.

Overview of Prochlorperazine Edisylate

Prochlorperazine belongs to the phenothiazine class of drugs, acting primarily as a dopamine antagonist. Its disylate salt form enhances solubility and stability, facilitating formulation into various dosage forms such as tablets, suppositories, and injections (1). The compound's global demand stems from its indicated uses across hospitals, clinics, and pharmacies. Given its importance, the drug's supply chain comprises a handful of specialized chemical manufacturers, many operating under strict regulatory oversight.

Leading Manufacturers and Suppliers

1. Jubilant Life Sciences

Jubilant Life Sciences, an India-based pharmaceutical and chemical manufacturer, is a prominent supplier of active pharmaceutical ingredients (APIs), including Prochlorperazine Edisylate. Known for its extensive API manufacturing capacity, Jubilant services both generic and branded drug markets globally. Its manufacturing facilities adhere to international standards such as cGMP and ISO certifications, ensuring compliance for markets like the US, Europe, and Asia (2).

2. Granules India

Granules India, another India-based manufacturer, supplies a broad portfolio of APIs, including phenothiazines like Prochlorperazine Edisylate. Their integrated manufacturing process benefits from optimized quality controls, enabling consistent supply. The company's strategic focus on export markets positions it as a key supplier to multinational pharmaceutical companies (3).

3. Mingde Chemical Industry

Based in China, Mingde Chemical Industry produces and exports API intermediates and finished APIs, including phenothiazine derivatives. The Chinese chemical sector's competitiveness, robust manufacturing infrastructure, and proximity to raw materials grant Mingde a significant role as a supplier for global markets (4).

4. Siegfried AG

A Swiss-based contract manufacturer, Siegfried AG specializes in APIs and intermediates with a reputation for high-quality standards. While primarily serving as a contract manufacturer, Siegfried also supplies Prochlorperazine Edisylate to branded and generic pharmaceutical firms, emphasizing innovation and regulatory compliance (5).

5. Other Notable Suppliers

  • DAIICHI SANKYO: A Japanese pharmaceutical company offering high-quality APIs, including phenothiazines, with a focus on safety and purity.
  • Hetero Labs: An Indian pharma company with a broad API portfolio, including antipsychotics and antiemetics, catering mainly to domestic and emerging markets.

Market Dynamics and Supply Chain Considerations

Regulatory Factors

Manufacturers must adhere to stringent regulatory standards such as the US FDA cGMP, European EMA guidelines, and WHO prequalification protocols. These regulations influence supplier qualification, quality assurance, and export capabilities (6). Suppliers with validated manufacturing processes and comprehensive compliance histories are preferred.

Raw Material Sourcing

The synthesis of Prochlorperazine Edisylate involves multiple chemical intermediates, often sourced from global suppliers of phenothiazine compounds and solvents. Fluctuations in raw material prices or supply disruptions can impact API production volumes.

Manufacturing Capacity and Scalability

Major suppliers like Jubilant and Granules have expanded capacity to meet growing global demand, especially amid rising prescriptions for antiemetics and antipsychotics. Capacity constraints remain a concern for smaller or less integrated manufacturers, potentially affecting availability.

Market Trends

The increasing global prevalence of nausea and psychiatric disorders sustains steady demand for Prochlorperazine Edisylate. Generic pharmaceutical companies predominantly supply the drug, with brand-name manufacturers focusing on niche indications.

Geopolitical and Economic Influences

Trade policies, tariffs, and geopolitical tensions influence supply chain stability. India's and China's roles as primary manufacturing hubs make regional policies impactful on global supply continuity.

Challenges in Sourcing

  • Quality Variability: Variations in manufacturing quality can impact regulatory approvals.
  • Supply Disruptions: Raw material shortages, geopolitical tensions, or logistical challenges, notably during the COVID-19 pandemic, threaten consistent supply.
  • Price Fluctuations: Market competition and raw material costs influence API pricing, requiring strategic sourcing and long-term supplier relationships.

Strategic Recommendations

  • Establish partnerships with multiple reputable suppliers to mitigate risks.
  • Prioritize suppliers with proven regulatory compliance and manufacturing scalability.
  • Engage in supplier qualification and audit protocols to ensure quality.
  • Monitor geopolitical and market developments influencing supply chains.
  • Consider vertical integration or in-house manufacturing for critical APIs where feasible.

Conclusion

Prochlorperazine Edisylate's supply landscape features established global suppliers rooted mainly in India, China, and Europe. The steady demand, combined with strict regulatory requirements, underscores the importance of reliable supply chains focused on quality, capacity, and regulatory adherence. Stakeholders must conduct thorough due diligence and diversify sourcing strategies to ensure uninterrupted access to this vital API.


Key Takeaways

  • Leading API suppliers include Jubilant Life Sciences, Granules India, Mingde Chemical Industry, and Siegfried AG.
  • India and China dominate the manufacturing landscape, with robust capacity and competitive pricing.
  • Regulatory compliance and manufacturing quality are critical in establishing reliable supplier relationships.
  • Raw material sourcing and geopolitical factors remain vital considerations impacting supply stability.
  • Strategic diversification and proactive supply chain management are essential for business continuity.

FAQs

Q1: What are the main regulatory considerations when sourcing Prochlorperazine Edisylate?
A: Suppliers must comply with international standards such as cGMP, EMA guidelines, and WHO prequalification. Regulatory validation, quality assurance, and documentation are fundamental to approval and market access.

Q2: How does raw material sourcing affect the supply of Prochlorperazine Edisylate?
A: Raw materials, including phenothiazine intermediates, are sourced globally. Disruptions or price fluctuations in these inputs can lead to production delays or increased costs.

Q3: Can smaller manufacturers reliably supply Prochlorperazine Edisylate?
A: While possible, smaller suppliers often face capacity constraints or compliance challenges. Due diligence and rigorous qualification processes are essential before engaging them.

Q4: What market factors influence the pricing of Prochlorperazine APIs?
A: Price determinants include raw material costs, manufacturing scale, regulatory compliance, market demand, and competition among API suppliers.

Q5: Are there any geopolitical risks associated with sourcing from India and China?
A: Yes, regulatory changes, tariffs, and trade tensions can impact supply stability. Diversification and establishing regional partnerships help mitigate these risks.


References

  1. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th Ed. (2018).
  2. Jubilant Life Sciences Annual Report 2022.
  3. Granules India Ltd. Corporate Overview.
  4. Mingde Chemical Industry Product Portfolio.
  5. Siegfried AG Corporate Blog.
  6. World Health Organization. WHO Good Manufacturing Practices (GMP) Guidelines for APIs.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.